Dr Reddy's Laboratories has settled a patent dispute in the US with the Switzerland-based drug maker Novartis Pharma over Exelon (rivastigmine tartrate), used in the treatment of a type of dementia of the Alzheimer's type. Under the terms of the agreement, Dr. Reddy's will not launch its generic rivastigmine tartrate capsules until sometime before the expiry of the Orange Book patents claiming rivastigmine. The exact date of launch and other terms of this agreement are confidential, Dr Reddy's informed the stock exchanges. In October 2007, Dr Reddy's received the final approval from US FDA on its ANDA for rivastigmine capsules. According to market research agency, IMS, the annual sales of this product in the US is around $199 million.
